Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

SABCS 2017

Published: 7 Dec 2017

Views: 1740

Rating:

Save

Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland

Prof Joensuu speaks at a SABCS 2017 press session about data from the phase III Synergism or Long Duration (SOLD) clinical trial.

Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment.

Read the news story for more.

Related Videos

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos

The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )

Insights into germline genetic screening of breast cancer patients

Dr Teresa Ramón y Cajal, Dr Marjanka Schmidt and Dr Seigo Nakamura

Insights into germline genetic screening of breast cancer patients ( Dr Teresa Ramón y Cajal, Dr Marjanka Schmidt and Dr Seigo Nakamura )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

Genomic testing: Awareness and effective communication between healthcare professionals and patients

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

More from ecancer